Del Frisco’s Steakhouse
1428-1432 Chestnut Street
Philadelphia, PA 19102
Date: Wednesday, June 11th, 11:30 am. Luncheon presentation at noon.
Program Presenter: H.H. Kim – Chief Executive Officer and President & Marshall H. Woodworth – Chief Financial Officer
H.H. Kim – Chief Executive Officer and President
Prior to his appointment as Chief Executive Officer and President of the Company, Mr. Kim was the General Counsel and a Senior Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs. Mr. Kim has been serving as a member of the Company’s Board since July 2021. Mr. Kim previously served as Executive Director of Dong-A ST from 2018 through 2020 and as Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. During his time at Dong-A ST and Dong-A Socio Holdings, he negotiated many significant transactions, including licensing and investment transactions. Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private, Swiss-based provider of scientific research and development services. Mr. Kim previously served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. He received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.
Marshall H. Woodworth – Chief Financial Officer
Marshall has more than 35 years of experience in financial roles of increasing responsibility including over 20 years of experience in life sciences and related sectors. Prior to joining MetaVia, Marshall held CFO roles with Nevakar Inc., Braeburn Pharmaceuticals Inc., Aerocrine AB and Furiex Pharmaceuticals Inc. During his career, Marshall has worked for a number of companies including: Eli Lilly, Dow Chemical, Monsanto, Milliken and others. Marshall brings a wealth of experience in private and public company management and stewardship and has extensive experience working with investors and analysts in the life science sector.
Throughout his career, Marshall has contributed to the success of companies by acting as a key resource and advisor to management, working closely with R&D and operations, and ensuring that finance functions are informed by a deep understanding of programmatic operations.
Marshall holds a Bachelor of Science degree from the University of Maryland College Park and an MBA from Indiana University in Bloomington.
ABOUT
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit www.metaviatx.com.
